NEW YORK /PRNewswire/ -- Global Cancer Immunotherapy Market to Reach $170.70 billion by 2028

The healthcare industry is a multi-billion-dollar market consisting of various verticals aimed at improving patient lives.The industry has experienced considerable advancement in terms of diagnosis and treatment, yet cancer remains as one of the leading causes of death.

Read the full report: https://www.reportlinker.com/p05740276 

Cancer acts as one of the major issues of the global healthcare industry, as it is the second leading cause of death all around the world (according to WHO).The effects of cancer have had a major impact on society across the world and currently accounts for almost 70% of death in low- and middle-income countries.

As per GLOBOCAN data, there were almost 14 million cancer cases globally in 2012, which claimed almost 8 million patient lives.As a result, significant scientific innovation is taking place in the field of oncology for the development of novel oncology medicines that are significantly propelling the growth of cancer treatment market.

Cancer immunotherapy or, immuno-oncology, is the treatment that utilises the body's own immune system to combat cancer. These immunotherapy treatments either boost the body's immune system or may act on immune system to identify and destroy the cancerous cells. Immunotherapy is a type of personalized medicine that works better for certain types of cancer. Globally, patients are displaying a positive response towards advanced cancer therapy drugs which effectively help manage and treat their medical conditions. This, in turn, is gradually increasing the adoption rate of the cancer immunotherapy drugs.

The cancer immunotherapy market consists of products such as monoclonal antibodies, check point inhibitors, cancer vaccines and other medicinal treatments such as adoptive cell therapies and oncolytic viral therapies used in the treatment of cancer.The market analysis report includes an in-depth examination of the key ecosystem players, key strategies, and developments taking place in this market.

Additionally, it includes market dynamics (market drivers, opportunities, and challenges) and industry analysis.The market has been classified based on different therapeutic indications, such as breast cancer, melanoma, colorectal cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, gastric cancer, and others.

Geographically, the market can be segmented into five distinct regions including North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World.

The purpose of the study is to gain a holistic view of the global cancer immunotherapy market in terms of various factors influencing the same, such as key market trends, competitive and regulatory aspects of the market, scientific innovations in the oncology field, etc.The scope of the report is centred upon conducting a detailed study of the solutions allied with cancer immunotherapy market, which involves drugs used in different therapeutic applications of cancer treatment.

The global cancer immunotherapy market is segmented into three different parts: 'by products', 'by therapeutic indication', and 'by region'.The report offers the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions.

The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

This research report aims at answering questions related to various aspects of the global market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The market by region has been further sub-segmented in various countries, and in each sub-segment the key market trends, list of the key players, and recent developments, have been discussed.


Executive Summary
The healthcare industry has made incredible advancement in diagnosis and treatment of all kinds of diseases that could not be cured earlier, yet cancer remains as one of the leading causes of death. As per the World Health Organisation (WHO) -- Cancer was responsible for an estimated 9.6 million deaths in 2018. The rising geriatric population is likely to increase the incidence and prevalence of cancer in the coming years. As per data from Surveillance, Epidemiology, and End Results (SEER) program of the U.S.-based government health agency National Cancer Institute (NCI), approximately 83-84% of the known cancer cases occur in people aged 50 years and above globally. The geriatric population is at an increased risk as cancer occurs due to genetic aberrations or mutations in the human DNA. In simpler terms, with age, our cells get damaged due to an unhealthy lifestyle like smoking or exposure to ultra-violet rays, and accumulation of these damaged cells (which recover fast at a younger age as compared to when we are old) over a lifetime is one of the prominent causes of cancer. According to WHO, cancer claimed 8.8 million lives in 2015 and accounted for almost 1 in 6 global deaths. In low- and middle- income countries, about 70% of deaths are caused due to cancer, resulting in a significant burden on the healthcare and economy of these countries. The treatment of cancer is long-term and involves extensive therapies that are expensive, and act as an economic burden on the patients and their families. It has been estimated that global spending on cancer therapies and supportive care drugs exceed $133 billion and is expected to increase to $200 billion by 2022.

Cancer Immunotherapy or, immuno-oncology, is the treatment that utilizes the body's self-immune system to combat cancer.The immunotherapy treatments either boost the body's immune system against cancer or acts as the immune system to identify the cancerous cells and destroy them.

Immunotherapy is precision (personalized) medicine that works better for some types of cancer; however, this treatment is now used for different types of cancer. The first immunotherapy treatment, Yervoy, was approved and commercialized in 2011 by US-based bio-pharmaceutical company, Bristol-Myers Squibb.

Recently with the discovery of new oncology targets and increased knowledge about cancer, newer immunotherapy options have been discovered. For e.g., approval of novel checkpoints (targets in the body of a patient with cancer) inhibitors against PD-1 and PD-L1, have revolutionized the immune-oncology market with their rapid uptake among the patients. The global cancer immunotherapy market was valued at $39.86 billion in 2017 and is anticipated to reach $170.70 billion by 2028. The rising prevalence of cancer around the world and high unmet medical needs of patients with cancer are stimulators for the growth of the cancer immunotherapy market. In addition, the advancements in precision medicine for immuno-oncology and rise in expenditure by pharmaceutical companies on R&D for cancer treatments, are contributing to the rise in demand for cancer immunotherapy as a treatment for cancer.

The purpose of the BIS Research study, Global Cancer Immunotherapy Market, is to gain a holistic view of the global cancer immunotherapy market against various factors influencing the market, such as the key market trends, competitive and regulatory aspects of the market, scientific innovations into oncology fields, etc.The scope of the report is centered upon a detailed study of the solutions allied with cancer immunotherapy market which involves immune-oncology drugs used in different therapeutic applications for cancer treatment.

The global cancer immunotherapy market is segmented into three different parts: 'by products', 'by therapeutic indication', and 'by region'.The global market value for cancer immunotherapy was estimated using these three different approaches and was validated against one another.

These segments are further segmented into several sub-segments to ease the market estimation.

Based on products, the market can be sub-segmented into monoclonal antibodies, check point inhibitors, cancer vaccine, and others.The market for monoclonal antibodies dominates the market in terms of revenue.

The growth of the monoclonal antibodies market is accredited to the efficacy of these targeted antibodies, rising demand for advanced oncology medicines along with an increase in the research and development facilities globally.However, Check Point Inhibitors exhibit a higher growth rate as they have shown to be more efficacious and have less toxicity as compared to other product classes.

These products have a novel mechanism of action which have revolutionized the cancer immunotherapy market.

Based on therapeutic indication, the market can be classified into seven major cancer types, which include breast cancer, melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, renal cell carcinoma, gastric cancer, and others. Among the different types of cancers, breast cancer is the leading contributor to metastatic cancer treatment market, while the highest CAGR is expected to be registered by NSCLC during the forecast period from 2018 to 2028.

Geographically, the market is sub-segmented into five distinct regions -- North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World.North America leads the market in terms of revenue, followed by Europe.

Within North America, the U.S. generated almost 96% of the total revenue share, and the rest 4 % of the revenue was generated by Canada in 2017. Within Europe, Germany dominated the market in 2017 with a revenue share of 16.73%. However, the market for Asia-pacific region is expected to demonstrate the highest growth rate, during the forecast period from 2018 to 2028, as compared to other regions.

The cancer immunotherapy market has a promising potential for growth in the coming years.The report provides an in-depth SWOT analysis of different key players of the market, supported by an extensive financial summary of each company.

The key players of the market are Aduro Biotech, Inc, Amgen Inc., AstraZeneca PLC, Boehringer Ingelheim, Bristol Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Gilead Sciences, Inc, among others.

Contact Clare: clare@reportlinker.com 
US: (339)-368-6001 
Intl: +1 339-368-6001